Introduction
, suggesting that Cenp-F might be an APC/C Cdh1 substrate. Consistently, Cenp-F has several KEN-boxes, motifs believed to be Cdh1 degrons (Pfleger and Kirschner, 2000) . Surprisingly, Cenp-F is farnesylated (Ashar et al., 2000) and this post-translational modification is required for its ability to efficiently target kinetochores (Hussein and Taylor, 2002) . More surprisingly, cells treated with farnesyl transferase inhibitors (FTI) accumulate Cenp-F, suggesting that farnesylation is also required for its turnover (Hussein and Taylor, 2002) .
Based on these observations, we hypothesised that Cenp-F is an APC/C Cdh1 substrate that needs to be farnesylated to be degraded. This hypothesis makes several predictions: first, Cenp-F degradation should initiate after anaphase; second, degradation should be dependent on one or more KEN-boxes and the CAAX farnesylation motif; and third, inhibition of Cdh1 or farnesyl transferase activity should block Cenp-F degradation specifically after anaphase onset. Here, we directly test these predictions by analysing GFP-tagged fusion proteins in living cells as they progress through mitosis, an approach used previously to great effect when studying, for example, mitotic cyclins, securin and Plk1 (Clute and Pines, 1999; Hagting et al., 2002; Lindon and Pines, 2004; Wolthuis et al., 2008) .
Results

A time-lapse assay to differentiate pre-and post-anaphase degradation
To determine when degradation of Cenp-F initiates, we first had to establish an experimental system with sufficient temporal resolution to distinguish between pre-and post-anaphase initiation events. To do this we used securin as a model protein. Degradation of securin initiates before anaphase, consistent with it being a Cdc20 substrate. However, deleting the D-box from securin converts it to a Cdh1 substrate; degradation now initiates after anaphase in a KEN-boxdependent manner (Hagting et al., 2002) .
We generated DLD-1-derived stable cell lines harbouring Cterminally GFP-tagged securin transgenes. These transgenes were also Myc-tagged to enable us to check expression by immunoblotting and immunofluorescence. The transgenes were integrated at a pre-defined genomic locus using FRT-Flp-mediated recombination, facilitating direct comparison of different fusions (O'Gorman et al., 1991) . Transgene expression was under tetracycline control, allowing us to study the first mitosis following induction. The parental DLD-1 line was also engineered to constitutively express a dsRed-tagged histone H2B, allowing us to monitor chromosome alignment and segregation.
To determine degradation kinetics, stably transfected cells were synchronised at G1-S using a single thymidine block (Fig. 1A) . The cells were then released from the block and tetracycline (Tet) added to induce transgene expression. Eight hours later, tetracycline was removed and the cells analysed by time-lapse microscopy. GFP fluorescence was measured every 2 minutes as cells progressed through mitosis. Degradation curves were then generated by plotting the GFP-fluorescence intensity as a function of time, with T 0 representing anaphase onset. Fluorescence intensities were normalised, with 100% representing the maximum value prior to or around anaphase, allowing us to generate degradation curves derived from multiple cells.
Consistent with previous observations (Hagting et al., 2002; Holland and Taylor, 2006) , degradation of securin-GFP initiated around 25 minutes prior to anaphase onset and degradation of securin-⌬D-GFP initiated at anaphase (Fig. 1B) . Furthermore, degradation of an Aurora-A-GFP fusion -a bone fide Cdh1 substrate -initiated at around 10 minutes after anaphase onset (Fig.  1B) . Thus, the time-lapse assay does indeed have sufficient temporal resolution to distinguish between degradation events initiated before and after anaphase onset.
Degradation of Cenp-F initiates after anaphase and is KEN-box-dependent
Having established an assay capable of resolving pre-and postanaphase degradation events, we turned our attention to Cenp-F, initially focusing on the C-terminal 630 amino acids (C630, Fig.  2A ). Importantly, we previously showed that this domain is cellcycle regulated, akin to the endogenous protein (Hussein and Taylor, 2002) . Following tetracycline-induction, GFP-C630 was detectable at kinetochores in prometaphase (Fig. 2B,D) , consistent with prior observations (Hussein and Taylor, 2002) . Analysis of the GFP-C630 degradation curves showed that proteolysis initiated ~6 minutes after anaphase (Fig. 2F) , consistent with our hypothesis that Cenp-F is an APC/C Cdh1 substrate. Cenp-F has seven KEN boxes and two of these, KEN6 and KEN7, are present in C630 ( Fig. 2A) . To determine whether these motifs are required for proteolysis of C630, we generated cell lines expressing GFP-tagged C630 fusions in which either KEN6 or KEN7 were mutated to AAA (Fig. 2B ). Both ⌬KEN mutants localised to kinetochores in prophase ( Fig. 2D and not shown). However, whereas the ⌬KEN6 mutant was degraded in a manner similar to GFP-C630, the ⌬KEN7 mutant was completely stabilised (Fig. 2F) . Thus, degradation of GFP-C630 requires a specific KEN box, again consistent with Cenp-F being an APC/C Cdh1 substrate. So far, we have not been able to determine why KEN7 is required for degradation of Cenp-F and the other six KEN motifs are not. Interestingly, mouse Cenp-F has only two KEN sequences, both of Journal of Cell Science 123 (3) , securinD-GFP (D, dark grey circles, n14 from four experiments) and Aurora-A-GFP (dark grey circles, n7 from one experiment). Immunoblots show the expression of the GFPfusion proteins. BubR1 was used as a loading control. Note that the lower mobility forms are more apparent in the securin⌬D-expressing line. This is because securin is also degraded in interphase by a phosphorylation-mediated SCF-dependent mechanism (Gil-Bernabe, 2006). The ⌬D mutant seems refractory to SCF-dependent degradation, resulting in the accumulation of the hyper-phosphorylated forms.
which are conserved in the human protein, namely KEN2 and KEN7.
To confirm that lessons learnt from C630 are relevant to the fulllength protein, we generated cell lines expressing GFP-tagged fulllength Cenp-F fusions (Fig. 2C) . The exogenous GFP-tagged Cenp-F appeared to behave like endogenous Cenp-F, localising to the nuclear envelope in late G2 before then targeting kinetochores in late prophase (supplementary material Fig. S1 ). Importantly, both GFP-Cenp-F and the ⌬KEN7 mutant localised to kinetochores in prophase (Fig. 2E) . Like GFP-C630, degradation of GFP-Cenp-F initiated after anaphase and was dependent on KEN7 (Fig. 2F) . Thus, taken together, these observations suggest that Cenp-F is degraded after anaphase in a KEN-dependent manner, arguing that it is indeed an APC/C Cdh1 substrate. Previously, we showed that ectopic expression of C630 delayed the cell cycle some time during G2 and/or mitosis (Hussein and Taylor, 2002) . We also showed that this delay was alleviated when the CAAX motif of C630 was mutated. Consistent with these observations, our time-lapse analysis showed that GFP-C630 delayed mitotic progression (see later). Whereas cells expressing GFP took ~49 minutes to proceed from nuclear envelope breakdown to anaphase, cells expressing GFP-C630 took ~73 minutes, largely due to delay in chromosome alignment. Mutating the CAAX motif alleviated this delay; cells expressing GFP-C630 C:S (whereby the cysteine in the CAAX motif is substituted with a serine residue) took ~59 minutes to complete mitosis. This affect does not seem to be due to the CAAX mutant being non-degradable; expression of GFP-C630 ⌬KEN7 also delayed chromosome alignment. In contrast to GFP-C630, expression of GFP-tagged full-length Cenp-F did not delay mitosis (data not show). Importantly, C630 lacks the binding site for Ndel1 and Nde1 (Vergnolle and Taylor, 2007) . One possibility therefore is that by displacing endogenous Cenp-F from kinetochores (see Hussein and Taylor, 2002) , expression of C630 reduces the levels of kinetochore-bound Ndel1 and Nde1, which in turn compromises chromosome alignment.
Post-anaphase degradation of Cenp-F is dependent on farnesylation
As mentioned above, in a previous study we showed that C630 is cell-cycle regulated, much like endogenous Cenp-F. More specifically, when C630 is constitutively expressed from a CMV promoter, it accumulates in G2 cells but is largely absent from G1 cells (Hussein and Taylor, 2002) . Interestingly, when we mutated the CAAX farnesylation motif of C630, it accumulated in G1 cells. In addition, when we treated HeLa cells with an FTI, endogenous Cenp-F accumulated in G1 cells (Hussein and Taylor, 2002) . On the basis of these indirect observations, we speculated that the degradation of Cenp-F is dependent on farnesylation. The new data shown here is consistent with the notion that Cenp-F is an APC/C Cdh1 substrate. However, there is no evidence to suggest that degradation of other APC/C Cdh1 substrates requires them to be farnesylated. Therefore, we used the time-lapse assay to determine more directly whether farnesylation is required for the initiation of Cenp-F degradation after anaphase.
To test whether the CAAX motif of Cenp-F is required for its degradation, we generated cell lines expressing GFP-tagged C630 and full-length Cenp-F fusions harbouring C:S mutations (Fig.  3A,B) . Consistent with our previous data, the C630 C:S mutant localised poorly to kinetochores (Fig. 3D) . Surprisingly, the fulllength C:S mutant was more readily detectable at some kinetochores, suggesting that in the absence of farnesylation, N-terminal sequences not present in C630 might stabilise Cenp-F at the kinetochore. However, quantification of Myc-tagged Cenp-F C:S localisation showed that it was dramatically reduced compared to wild type (supplementary material Fig. S2 ).
First, we wanted to confirm that Cenp-F is indeed farnesylated and that this could be inhibited both by mutation of the CAAX motif and by exposure to FTIs. To do this, we cultured cells expressing GFP-tagged C630 in the alternative farnesyl transferase substrate, anilinogeraniol (AGOH) (Troutman et al., 2005) . AGOH is a prodrug that is converted to 8-anilinogeranyl diphosphate (AGPP) in cells. This in turn can be used by farnesyl transferases as a substrate to modify CAAX motifs, thereby adding the AG moiety instead of a natural farnesyl group. The advantage of this approach is that an anti-AG antibody can then be used to detect the modified protein. GFP-tagged C630 was then immunoprecipitated and the immune complexes blotted with an antibody that recognises the AG moiety. The anti-AG antibody recognised GFP-tagged C630 (Fig. 3C ), confirming that this proteins is indeed farnesylated in cells, and that this is unaffected by mutation of KEN7. However, mutating the cysteine residue in the CAAX motif to serine, or treating the cells with an FTI, abolished anti-AG reactivity, confirming that farnesylation was blocked.
Analysis of the degradation curves showed that mutating the CAAX farnesylation motif stabilised both GFP-C630 and full-length Cenp-F (Fig. 3E) . Similarly, culturing the cells with an FTI blocked their post-anaphase degradation. Note that the FTI did not affect the degradation of securin, securin⌬D or Aurora A (not shown). Clearly therefore, this more direct analysis argues that farnesylation of Cenp-F is indeed required for its post-anaphase degradation.
Cenp-E tail turnover is dependent on farnesylation
As far as we are aware, the role of farnesylation in a cell-cycleregulated degradation process is unprecedented. This in itself raises numerous questions, one of which is whether this phenomenon is restricted to Cenp-F. Interestingly, the kinetochore-associated kinesin Cenp-E is also farnesylated (Ashar et al., 2000) . Furthermore, Cenp-E is degraded sometime shortly after mitosis (Brown et al., 1994) . Therefore, we asked whether farnesylation of Cenp-E is required for its post-mitotic degradation. To do this, by analogy with Cenp-F, we focused on the C-terminal region of Cenp-E, referred to as the Cenp-E tail (Fig. 4A ). We generated cell lines expressing the Cenp-E tail as a GFP-tagged fusion (Fig. 4 B) . The GFP-tagged Cenp-E tail was recruited to kinetochores in prometaphase and was then depleted from kinetochores following chromosome alignment, suggesting that it is useful proxy for the Journal of Cell Science 123 (3) full-length protein (supplementary material Fig. S4 ). Importantly, when cells were cultured in AGOH and the Cenp-E tail immunopurified, the fusion protein was detected by the anti-AG antibody (Fig. 4C) , confirming that the fusion protein can be farnesylated. Moreover, mutation of the CAAX motif or exposure of the cells to an FTI blocked this modification (Fig. 4C) .
Note that ectopic expression of the Cenp-E tail induced a prolonged mitotic delay (supplementary material Fig. S4 ). This has thus far hindered our attempts to analyse the degradation of the Cenp-E tail by time-lapse GFP imaging. Therefore, to test the role of farnesylation in Cenp-E turnover, we turned to a less direct but nevertheless informative approach. We first induced expression of the GFP-tagged Cenp-E tail, then fixed the cells and stained them with propidium iodide to determine the DNA content. We then compared the DNA-content profiles of the whole population and the GFP-positive subpopulation. In cells expressing the tail, virtually all the GFP-positive cells had 4N DNA contents, consistent with the Cenp-E tail only being present in G2 and M-phase cells (Fig.  4D) . However, when the CAAX motif was mutated or when the cells were cultured with an FTI, cells with 2N DNA contents were now GFP-positive, indicating the accumulation of the Cenp-E tail in G1 cells. To confirm this, we analysed cells by immunofluorescence, co-staining for cyclin B1, which is absent from G1 cells. In cells expressing the Cenp-E tail, GFP fluorescence was very low but, when detectable, it was only present in mitotic cells staining positive for cyclin B1 (Fig. 4E) . By contrast, the C:S mutant was readily detectable in most interphase cells, including those negative for cyclin B1, again indicating its accumulation in G1 cells. The Cenp-E tail was detectable in cyclin-B1-negative cells treated with an FTI (Fig. 4E ). These observations therefore are entirely consistent with the notion that the Cenp-E tail also needs to be farnesylated to be degraded.
Cdh1 RNAi only partially inhibits Cenp-F degradation
Our observations showing that degradation of Cenp-F initiates after anaphase in a KEN-box-dependent manner suggests that Cenp-F is an APC/C Cdh1 substrate. However, the fact that Cenp-F, along with Cenp-E, also needs to be farnesylated in order to be degraded is a feature not typical of other known APC/C Cdh1 substrates. Therefore, we wished to ask more directly whether Cdh1 is required for Cenp-F degradation. To this end, we used siRNA duplexes to repress Cdh1 levels by more than 90% (Fig. 5A) . Importantly, this level of repression was sufficient to almost completely block degradation of an Aurora-A-GFP fusion; after 2 hours fluorescence levels had slowly decreased to ~85% (Fig. 5B) . The effect of Cdh1 RNAi on C630 and full-length Cenp-F was less straightforward. Following anaphase onset, degradation of both C630 and the fulllength protein was initiated with kinetics similar to those in control cells (Fig. 5C ). However, whereas the levels of C630 and full-length Cenp-F fell to less than 30% within 120 minutes, their levels only fell to ~60% following Cdh1 RNAi. One possible explanation for this result might be incomplete RNAi-mediated repression; perhaps the residual Cdh1 protein was sufficient to trigger timely degradation of Cenp-F, but not sufficient to push the process to completion. To test this possibility, we turned to mouse embryo fibroblasts (MEFs) that completely lack Cdh1 protein (Garcia-Higuera et al., 2008). 
Cenp-F degradation occurs normally in Cdh1-null MEFS
To test the role of Cdh1 more rigorously, we immortalised CDH1 +/+ and CDH1 -/-mouse embryo fibroblasts (iMEFs) and then transiently transfected them with expression vectors encoding GFP-tagged fusions and analysed them by time-lapse microscopy 48 hours later. First, we wished to determine whether the lessons learnt using human DLD-1 cells also applied to mouse fibroblasts. Importantly, GFP-C630 was degraded in CDH1 +/+ iMEFs, with initiation occurring shortly after anaphase (Fig. 6A ). In addition, this was blocked when either KEN7 or the CAAX motif was mutated (Fig.  6A) . Thus, the mechanisms responsible for Cenp-F degradation appear to be conserved between mouse and human cells. Therefore we then turned to the CDH1 -/-iMEFs. Immunoblotting confirmed that CDH1 -/-iMEFs were indeed Cdh1-deficient (Fig. 6B) . Furthermore, a GFP-tagged Aurora B fusion was stabilised in CDH1 -/-iMEFs, confirming that these cells were Cdh1-deficient. Strikingly, however, GFP-C630 was degraded in CDH1 -/-iMEFs in a manner completely indistinguishable from that observed in CDH1 +/+ cells (Fig. 6A ). This result is unambiguous, demonstrating that Cdh1 is not essential, at least for the degradation of GFP-tagged C630.
One possible explanation for the above result could be that these iMEFs had adapted; because this cell lineage never contained Cdh1, perhaps they bypassed the requirement for Cdh1 by upregulation of alternative pathways. To address this, we immortalised MEFs harbouring a conditional CDH1 gene whereby exons 2 and 3 are flanked by LoxP sites (Garcia-Higuera et al., 2008) . These iMEFs were then infected for 48 hours with an adenoviral vector expressing Cre to recombine the LoxP sites. GFP-C630 was transiently transfected into the Cdh1-null cells and analysed by time-lapse. Importantly, this allowed us to analyse the degradation of GFP-C630 in the first cell cycles following inactivation of CDH1. However, despite efficient inactivation of CDH1, GFP-C630 was degraded normally (data not shown), further supporting the notion that Cdh1 is not required for the post-anaphase degradation of Cenp-F.
APC/C
Cdc20 contributes to post-mitotic degradation of Cenp-F The observation that GFP-C630 is degraded normally in Cdh1-null cells is somewhat perplexing as all the prior evidence is consistent with Cenp-F being an APC/C Cdh1 substrate. Specifically, as shown above, Cenp-F is degraded after anaphase onset in a KEN-boxdependent manner, a feature believed to be typical of Cdh1-dependent proteolysis (Pfleger and Kirschner, 2000) . However, these lines of evidence are circumstantial and evidence is emerging that the degradation of some mitotic regulators previously believed to be APC/C Cdh1 substrates, such as Plk1, are in fact not dependent on Cdh1 (Floyd et al., 2008; Garcia-Higuera et al., 2008) . Consistent with this, a GFP-Plk1 fusion was degraded normally in Cdh1-null Journal of Cell Science 123 (3) 
Fig. 6. Cenp-F is degraded normally in Cdh1-null iMEFS. (A)Line graphs showing the mean degradation over time of GFP-C630 (WT) in wild-type (green circles, n19 from three experiments) and CDH1
-/-iMEFs (green circles, n13 from four experiments); GFP-C630 C:S in wild-type (yellow circles, n13 from two experiments) and CDH1 -/-iMEFs (yellow circles, n8 from one experiment); and GFP-C630 KEN7 in wild-type (red circles, n12 from two experiments) and CDH1 -/-iMEFs (red circles, n10 from three experiments). (B)Line graphs showing the mean degradation over time of: GFP-Aurora-B in wild-type (grey circles, n11 from two experiments) and CDH1 -/-iMEFs (black circles, n14 from two experiments); GFP-Plk1 in wild-type (grey circles, n9 from two experiments) and CDH1 -/-iMEFs (black circles, n3 from two experiments). iMEFs (Fig. 6B) . One question immediately arises: if Cdh1 is not essential for Cenp-F degradation, then is the APC/C involved, and if so, is it also Cdc20-dependent?
To address whether the APC/C is required for Cenp-F degradation, we transfected RPE cells with siRNA duplexes to repress two APC/C subunits, namely APC2 and APC8. Because inhibition of APC/C was anticipated to induce mitotic arrest prior to the point in the cell cycle where Cenp-F is normally degraded, we used the CDK1 inhibitor Roscovitin to drive the cells out of mitosis. At various time points after mitotic exit, cells were harvested and analysed by immunoblotting. Importantly, under these conditions, APC/C-proficient cells degraded securin, cyclin B1 and Cenp-F: within 1 hour of adding Roscovitin, these proteins were undetectable (Fig. 7A) . By contrast, in cells deficient for either APC2 or APC8, securin, cyclin B1 and Cenp-F were still clearly detectable after 2 hours. Thus, these observations demonstrate that Cenp-F degradation is APC/C-dependent.
Next, we used a similar approach to determine whether degradation of Cenp-F was also dependent on Cdc20. RPE cells were transfected with siRNA duplexes designed to repress Cdc20 and Cdh1 and, once again, mitotically arrested cells were driven out of mitosis with Roscovitin and then analysed by immunoblotting. As expected, repression of Cdc20 stabilised two bona fide APC/C Cdc20 substrates, namely securin and cyclin B1 (Fig.  7B) . Both securin and cyclin B1 were, however, degraded following Cdh1 RNAi. Consistent with it being a Cdh1 substrate, Aurora A was stabilised following Cdh1 RNAi, but it was still degraded after inhibition of Cdc20. Note , however, that Aurora A degradation is delayed following Cdc20-RNAi; for reasons that are not entirely clear, Cdc20-RNAi cells are more resistant to Roscovitin-stimulated mitotic exit. Significantly, repression of Cdc20 stabilised Cenp-F, suggesting that Cdc20 does indeed play a role in Cenp-F degradation. If this is the case, then the notion that APC/C activation switches from being dependent on Cdc20 to being dependent on Cdh1 following anaphase would appear to be too simplistic. Our data suggest that APC/C Cdc20 contributes to the post-anaphasedependent degradation of Cenp-F. Consistent with the time-lapse data (Fig. 5C) , degradation of Cenp-F did not go to completion following Cdh1 RNAi (Fig. 7B) . Although the analysis of Cdh1-null MEFs demonstrates that Cdh1 is not essential for Cenp-F degradation (Fig. 6) , taking both the RNAi data and the MEF-based data into account, we suggest that in a normal cell, degradation of Cenp-F is initiated by APC/C Cdc20 and then driven to completion by APC/C Cdh1 .
Discussion
Cenp-F was previously shown to be degraded sometime during or after mitosis (Liao et al., 1995) . However, exactly when, how and why Cenp-F is degraded remained unclear. Here, we show that degradation of GFP-tagged Cenp-F fusions initiates about 6 minutes after anaphase onset and is dependent on a C-terminal KEN-box. Although this suggests that Cenp-F is an APC/C Cdh1 substrate, RNAi-mediated repression of Cdh1 in human cells only partially inhibits Cenp-F degradation. Moreover, mouse fibroblasts completely lacking Cdh1 degrade Cenp-F normally. By contrast, RNAi-mediated repression of Cdc20 stabilises Cenp-F, arguing that Cenp-F is in fact a Cdc20 substrate. Below, we rationalise these observations and, as previously suggested by Floyd, Pines and Lindon (Floyd et al., 2008) , we argue that in contrast to the Cdc20/Cdh1 'anaphase-switch' model, APC/C Cdc20 does in fact contribute to post-anaphase degradation of mitotic regulators.
Both APC/C Cdc20 and APC/C Cdh1 contribute to Cenp-F degradation
Here, we used time-lapse microscopy to study the degradation of GFP-tagged Cenp-F fusion protein. This approach enabled the study of individual cells, thus providing a level of temporal resolution that can be correlated with chromosome alignment and segregation. To allow a direct comparison of various mutants we used a system that allows the generation of isogenic tetracycline-inducible stable cell lines. Nevertheless, a key issue is whether the behaviour of the exogenous GFP-tagged protein reflects that of endogenous Cenp-F. We believe that it does for two reasons. First, GFP-Cenp-F localises similarly to endogenous Cenp-F. During G2, it accumulates in the nucleus but is excluded from nucleoli, then goes to the nuclear envelope at the onset of prophase and finally binds kinetochores in mitosis (supplementary material Fig. S1 ). Second, analysis of endogenous Cenp-F expression by immunofluorescence microscopy and immunoblotting is entirely consistent with the data derived from the time-lapse studies (data not shown). Indeed, this approach has been extremely informative when studying the degradation of a number of mitotic regulators (Clute and Pines, 1999; Hagting et al., 2002; Lindon and Pines, 2004; Wolthuis et al., 2008) .
Because degradation of GFP-Cenp-F occurred after anaphase, and in a KEN-box-dependent manner, our initial hypothesis was that Cenp-F was an APC/C Cdh1 substrate. Consistently, Cdh1 RNAi inhibited Cenp-F degradation. However, although Cdh1 RNAi almost completely blocked Aurora A degradation, the effect on GFP-Cenp-F was only partial. One explanation for this could be that residual Cdh1 allows APC/C-mediated ubiquitylation to continue, but only of its preferred or more processive substrates (Rape et al., 2006) . If Cenp-F is a particularly processive substrate, then the residual APC/C Cdh1 activity left following RNAi might be sufficient to partially degrade Cenp-F, although having no effect on Aurora A. However, analysis of iMEFs clearly shows that in the complete absence of Cdh1, GFP-Cenp-F is degraded normally, even though GFP-Aurora-B is stabilised (Fig. 6 ). This effect is not limited to Cenp-F because GFP-Plk1 was also degraded normally in Cdh1-null iMEFs, consistent with recent reports (Floyd et al., 2008; Garcia-Higuera et al., 2008) . Although this raises the possibility that another E3 ligase might be involved in Cenp-F ubiquitylation, we suspect that this is not the case because inhibition of either APC2 or APC8 stabilised Cenp-F. Taken together with the observation that Cdc20 RNAi also stabilised Cenp-F, our data argues that APC/C Cdc20 plays a role in Cenp-F degradation. Although this notion is inconsistent with the idea that APC/C switches from Cdc20-to Cdh1-mediated degradation at anaphase onset, it is consistent with a recent study showing that even though Cdh1 RNAi inhibited degradation of Aurora A and B, there was little effect on other presumed Cdh1 substrates such as Plk1 (Floyd et al., 2008) .
On the basis of the above, we therefore favour the idea that APC/C Cdc20 plays a key role in the post-anaphase degradation of Cenp-F. However, if this is the case, how can we explain the fact that Cdh1 RNAi partially inhibits degradation of GFP-Cenp-F? We suggest that in unperturbed cells, both APC/C Cdc20 and APC/C Cdh1 are involved in ensuring the complete degradation of Cenp-F. Thus, shortly after anaphase, Cdc20 mediates the initial rapid degradation of Cenp-F, and then as Cdh1 becomes active it continues the process through to completion. Following Cdh1 RNAi, we suggest that APC/C Cdc20 functions normally, explaining the initial phase of Cenp-F degradation. However, we suspect that the residual levels of Cdh1 following RNAi are sufficient to result in Cdc20 destruction, thus bringing the degradation of Cenp-F to a halt at about 60 minutes after anaphase. Indeed, it was previously shown that Cdc20 is degraded normally in Cdh1 RNAi cells (Floyd et al., 2008) . However, in Cdh1-null cells, where there is no APC/C Cdh1 activity to inactivate Cdc20, APC/C Cdc20 -mediated degradation of Cenp-F continues unabated. In a normal cell, however, Cenp-F degradation continues for at least 120 minutes after anaphase, presumably long after Cdc20 has been degraded. This suggests that when Cdh1 is present, it is responsible for Cenp-F degradation once Cdc20 has been destroyed: otherwise, in a non-RNAi cell, degradation of Cenp-F would stop within about 60 minutes post-anaphase. This explanation suggests that either Cdc20 or Cdh1 can recruit Cenp-F to the APC/C after anaphase onset. Alternatively, perhaps Cenp-F binds the APC/C directly, independently of Cdc20 or Cdh1, so that it is then ubiquitylated once the APC/C is activated by either co-factor. As we discuss below, degradation of Cenp-F is dependent on it being farnesylated. Although there is no evidence to support this notion at present, one possibility is that Cenp-F interacts with the APC via a novel farnesylation-dependent mechanism and it is then ubiquitylated irrespective of which activating co-factor is bound.
Cenp-F needs to be farnesylated to be degraded
Several years ago it was reported that FTIs induce chromosome alignment and segregation defects during mitosis (Crespo et al., 2001; Schafer-Hales et al., 2007) . Because Cenp-E and Cenp-F have been shown to be farnesylated, these FTI-induced effects might be due to dysfunction of Cenp-E and/or Cenp-F (Ashar et al., 2000; Schafer-Hales et al., 2007) . Previously we showed that FTIs inhibit Cenp-F turnover: however, whether the FTI affected turnover of Cenp-F during interphase or mitosis was unclear. Here, we show that farnesyl transferase activity is required for the post-anaphase degradation of Cenp-F. Importantly, this effect of the FTI does not appear to be indirect, for example via inhibition of the ubiquitin proteasome pathway Time-lapse and immunoblot analysis showed that in the presence of the FTI, degradation of securin, securinD and Aurora A occur normally (data not shown). Furthermore, degradation of Cenp-F is absolutely dependent on its CAAX farnesylation motif. Importantly, this phenomenon is not a peculiarity of Cenp-F; we show here for the first time that the Cenp-E tail also needs to be farnesylated in order to be degraded.
Protein farnesylation is typically involved in targeting proteins to membranes and, as far as we are aware, farnesylation has not previously been implicated as a signal for ubiquitin-mediated degradation. One possibility is that farnesylation targets Cenp-E and Cenp-F to membranes and that this in turn allows them to be degraded. Although Cenp-F binds the nuclear membrane just prior to mitosis (Hussein and Taylor, 2002) , there is no evidence to suggest that Cenp-E associates with membranes, so we suspect that this explanation is unlikely. Also, the C-terminal 103 amino acids of Cenp-F, which contains both the KEN-box and the CAAX motif, is degraded after anaphase without any apparent localisation to the nuclear membrane or any other specific location within the cell (data not shown). Note that farnesylation of Cenp-E and Cenp-F is not just required for their degradation because their correct localisation during mitosis also requires farnesylation (Hussein and Taylor, 2002; Schafer-Hales et al., 2007) . Furthermore, although expression of C630 delays progression through G2 and/or M phase, expression of the CAAX mutant does not (Hussein and Taylor, 2002) . We suspect therefore that farnesylation of Cenp-E and Cenp-F plays a more significant role in their overall functions. Interestingly, farnesylation of Ras2 in budding yeast increases its affinity for adenylyl cyclase by 100-fold, independent of any membrane localisation (Kuroda et al., 1993) . In addition, farnesylation of Ykt6 increases its -helical content, inducing a more compact and stable conformation (Pylypenko et al., 2008) . Perhaps farnesylation of Cenp-E and Cenp-F similarly promotes conformational changes and, in doing so, increases their affinity for various binding partners. This, in turn, regulates their localisation, function and degradation.
The role of Cenp-F degradation
Elevated Cenp-F expression has been associated with poor prognosis in patients with breast cancer, leading to the suggestion that Cenp-F overexpression might contribute to tumorigenesis (O'Brien et al., 2007) . Surprisingly, we observed no obvious mitotic or cell-cycle defects following overexpression of various non-degradable Cenp-F mutants (data not shown) and as such the role of Cenp-F degradation remains unclear. One possibility is that Cenp-F degradation plays roles in contexts outside of mitosis. For example, Cenp-F inhibits the transcription factor ATF4 (Zhou et al., 2005) , which has been implicated in numerous post-mitotic phenomenon including long-term memory and synaptic plasticity (Ameri and Harris, 2008) . Cenp-F can also bind to Rb (Rattner et al., 1993) , which apart from its well-characterised role in the cell cycle, also activates transcription of muscle-specific genes (Novitch et al., 1996; Novitch et al., 1999) . Cenp-F orthologues in mouse and chicken have been implicated in muscle differentiation (Papadimou et al., 2005; Robertson et al., 2008) , raising the possibility that Cenp-F might regulate Rb during this process. Finally, Cenp-F also interacts with the dynein adapters Ndel1, Nde1 and Lis1 (Liang et al., 2007; Stehman et al., 2007; Vergnolle and Taylor, 2007) . These proteins are essential for regulating nuclear translocation during neuronal migration and for neuron positioning during cortical development (Shu et al., 2004) . Because APC/C Cdh1 also has important roles in post-mitotic neurons (Stegmuller and Bonni, 2005) , this raises the possibility that Cenp-F degradation might be important during neuron migration and positioning.
Materials and Methods
Expression constructs encoding APC/C substrates
The securin and Plk1 cDNAs were kind gifts from Jonathon Pines (Gurdon Institute, Cambridge, UK) and René Medema (University Medical Center, Utrecht, Netherlands), respectively. Aurora A and B plasmids were as previously described (Girdler et al., 2006) . A Cenp-F cDNA encoding amino acids 632-3113 was a kind gift from Wen-Hwa Lee (University of Texas Health Science Center, San Antonio, TX). cDNA encoding the N-terminal 750 amino acids was generated by RT-PCR amplification of mRNA from HeLa cells and was then subcloned into a vector encoding the C-terminal 2363 amino acids. All cDNAs were then cloned into a pcDNA5/FRT/TO-based vector (Invitrogen) modified to include a N-or C-terminal GFP tag. Some constructs also contained a Myc-tag. KEN and C:S mutants were created by site-directed mutagenesis (QuickChange, Stratagene).
Cell culture and generation of stable cell lines
DLD-1 cells and MEFs were cultured as described previously (Taylor et al., 2001) . Thymidine (Sigma) was used at 2 mM, SCH 66336 (Hussein and Taylor, 2002) at 1 M, AGOH (Troutman et al., 2005) at 30 M, and tetracycline (Sigma) at 1 g/ml.
An open reading frame (ORF) encoding histone H2B (Morrow et al., 2005) was cloned into pDsRed-Monomer-N1 to create a histone-H2B-dsRed ORF (BD Biosciences). This plasmid was then linearised and transfected into DLD-1 LacZeo/TO cells (Girdler et al., 2006) using Lipofectamine Plus (Invitrogen). Transfected cells were selected in 8 ug/ml Blasticidin (Melford), 60 ug/ml Zeocin (Invitrogen) and 0.75 mg/ml G418 (Sigma). DsRed-positive cells were then isolated by flow cytometry using a FACSAria (BD Biosciences) and seeded into 96-well plates to generate clonal cell lines. The pcDNA5/FRT/TO vectors encoding GFP-tagged APC/C substrates were then co-transfected with pOG44 into DLD1 LacZeo/TO Histone-H2B-dsRed cells as previously described (Tighe et al., 2004) .
Antibody techniques
Immunofluorescence analysis was performed essentially as described (Taylor et al., 2001 ) using the following antibodies: 4A6 mouse anti-Myc, (Upstate, 1:1000); sheep anti-Bub1 (Taylor et al., 2001) . Fluorescence microscopy was performed using a Zeiss Axiovert 200 equipped with epifluorescence and a Photometrics Cool Snap HQ CCD camera driven by Metamorph software (Universal Imaging). Immunoblot analysis was done as previously described (Taylor et al., 2001) , with proteins transferred onto either nitrocellulose or PVDF membranes. Cenp-F immunoblots were transferred to nitrocellulose membranes as previously described (Tighe et al., 2004) . The following antibodies were used: 4A6 mouse anti-Myc (1:1000; Upstate); sheep anti-Bub3 (1:1000; SB3.1), sheep anti-BubR1 (Taylor et al., 2001) , rabbit anti-GFP (1:5000; Abcam), DH01 mouse anti-Cdh1 (1:200; Abcam) mouse anti-cyclin B1 (1:100; GNS1, Abcam).
Farnesylation
To analyse protein farnesylation, DLD1 cells were treated with the AGOH analogue for 38-48 hours as previously described (Troutman et al., 2005) . The cells were then lysed and soluble extracts prepared as described (Morrow et al., 2005) . Anti-Myc (4A6) or anti-IgG antibodies coupled to protein G Sepharose (Amersham) were added to cell lysates for 1-2 hours and collected by centrifugation. The beads were washed with lysis buffer, then the proteins eluted in SDS sample buffer. Samples were resolved by SDS-PAGE, transferred to nitrocellulose and blotted with mouse anti-Myc and mouse anti-AGOH antibodies (Troutman et al., 2005) .
Time-lapse microscopy
For time-lapse imaging, cells were cultured in multi-well chamber slides (Lab-Tek, Nunc). Images were taken using a manual Axiovert 200 (Zeiss) microscope equipped with a PZ-2000 automated stage (Applied Scientific Instrumentation) and an environmental control chamber (Solent Scientific), which maintained cells at 37°C in a humidified stream of 5% CO 2 . Shutters, filter wheels and point visiting were driven by Metamorph software (MDS analytical technologies) and images taken using a CoolSNAP HQ camera (Photmetrics). Images were taken every two minutes for 24 hours, with a 40ϫ objective. The time-lapse images were analysed using Metamorph sofware in which boxes were drawn around individual cells, pixel intensities taken for each time frame, and background intensities subtracted. The GFP fluorescence was then normalised to the maximum intensity before or around anaphase for each individual cell and plotted as a percentage against time, with 0 minutes being set as anaphase onset.
Cdh1 RNAi
To repress Cdh1, approximately 2ϫ10 4 DLD1 cells were treated with 50 nM ONTarget smartpool siRNA duplexes (5Ј-CCACAGGAUUAACGAGAAU-3Ј, 5Ј-GGAACACGCUGACAGGACA-3Ј, 5Ј-GCAACGAUGUGUCUCCCUA-3Ј, 5Ј-GAAGAAGGGUCUGUUCACG-3Ј, Dharmacon) as per the manufacturer's instructions. Briefly, siRNA duplexes were mixed with 2 l Interferin (Autogen Bioclear) in media without serum and antibiotics, incubated for 15 minutess, then added to the cells with media containing serum and antibiotics.
Mouse embryo fibroblasts
Immortalised CDH1
+/+ and CDH1 -/-MEFs were cultured as previously described (Garcia-Higuera et al., 2008) . iMEFs were transiently transfected with the GFP-tagged constructs using ProFection calcium phosphate transfection kit (Promega) as per the manufacturers instructions. Briefly, 1.35ϫ10 4 cells were transfected with approximately 400 ng of DNA. DNA precipitates were then washed away after 24 hours.
CENP-E analysis
A CENP-E tail cDNA encoding amino acids 1572-2606 was subcloned into a pcDN5/FRT/TO-based vector modified to contain an N-terminal Myc-LAP tag. The LAP tag is comprised of GFP-Tev-S-peptide as described previously (Cheeseman et al., 2004) . For DNA content measurements, the CENP-E tail was induced for 24 hours, the cells then fixed in 70% ethanol over night, followed by staining with propidium iodide. The cells were then analysed using a Becton Dickinson LSR II. For immunofluorescence, cells were grown on acid-washed, glass coverslips coated with poly-L-lysine (Sigma-Aldrich), pre-extracted for 90 seconds in MTSB (100 mM PIPES pH 6.8, 0.1% Triton X-100, 0.1 mM CaCl 2 , 1 mM MgCl 2 ) and fixed in 4% formaldehyde in MTSB. Cells were blocked in 2.5% FBS, 2 M glycine, 0.1% Triton X-100 in PBS for 1 hour. Antibody incubations were conducted in the blocking solution for 1 hour. The DNA was detected using DAPI and cells were mounted in Prolong Antifade (Invitrogen). Images were collected using a Deltavision Core system (Applied Precision) controlling an interline charge-coupled device camera (Cooldsnap, Raper). Images were deconvolved and maximum intensity 2D projections were assembled for each image using softWoRx (Applied Precision). Where indicated cells were treated with FTI-277 (Calbiochem).
APC and Cdc20 RNAi
hTERT-RPE1 cells (a kind gift from Kip Sluder, University of Massachusetts, Worcester, MA) were cultured in D-MEM plus 8% FCS, 100 U/ml penicillin, and 100 g/ml streptomycin. ON-TARGET-plus SMARTpools of siRNA (Dharmacon) targeting APC2 (L-003200-00), APC8 (Cdc23, L-009523-00), Cdc20 (L-003225-00) and Cdh1 (FZR1, L-015377-00) were transfected using Lipofectamine 2000 according to manufacturer's instructions. Cells were then arrested in mitosis using nocodazole at 250 ng/ml for 15 hours. Mitotic cells were harvested by selective detachment in PBS at 37°C. 50 M Roscovitin was then added for 1 hour. Cell lysates were then separated by SDS-PAGE, proteins blotted on to nitrocellulose membranes then probed with antibodies against CENP-F (Abcam), cyclin B1 (GNS1, Santa Cruz Biotechnology), Securin (Abcam), APC3/Cdc27 (Transduction Labs), APC8 (BioLegend), Cdc20 (E7, Santa Cruz Biotechnology) and Cdh1 (NeoMarkers).
